These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26139987)

  • 21. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging treatments for hepatitis C.
    Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
    World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular basis for responsiveness to anti-viral therapy in hepatitis C.
    Polyak SJ; Gerotto M
    Forum (Genova); 2000; 10(1):46-58. PubMed ID: 10717257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative interferons and immunomodulators in the treatment of hepatitis C.
    Alao H; Jake Liang T
    Liver Int; 2014 Feb; 34 Suppl 1():133-8. PubMed ID: 24373090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of interferon in the new era of hepatitis C treatments.
    Parekh PJ; Shiffman ML
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-free regimens for hepatitis C: combine and conquer.
    Martel-Laferrière V; Bichoupan K; Dieterich DT
    BioDrugs; 2014 Apr; 28(2):161-9. PubMed ID: 24170615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
    Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C: epidemiology, diagnosis, natural history and therapy.
    Pol S; Vallet-Pichard A; Corouge M; Mallet VO
    Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.